FIL1h Antikörper

Produktnummer ABIN5564285

Produktdetails anti-FIL1h Antikörper

Target: FIL1h (Interleukin 1 eta (FIL1h))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser FIL1h Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA

Spezifität: Recognizes human IL-36beta.

Kreuzreaktivität: Human

Keine Kreuzreaktivität: Maus

Kreuzreaktivität (Details): Does not cross-react with mouse IL-36beta and IL-36gamma.

Reinheit: >95 % (SDS-PAGE)

Immunogen: Recombinant human IL-36beta.

Klon: Jacky-1

Isotyp: IgG1

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: Lot specific

Buffer: In PBS containing 10 % glycerol and 0.02 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Short Term Storage: +4°C
Long Term Storage: -20°C
Stable for at least 1 year after receipt when stored at -20°C.

Haltbarkeit: 12 months

Details zu FIL1h

Target: FIL1h (Interleukin 1 eta (FIL1h))

Andere Bezeichnung: IL-36beta (FIL1h Produkte)

Synonyme: 2310043N20Rik antikoerper, Il36b antikoerper, FIL1 antikoerper, FIL1-(ETA) antikoerper, FIL1H antikoerper, FILI-(ETA) antikoerper, IL-1F8 antikoerper, IL-1H2 antikoerper, IL1-ETA antikoerper, IL1F8 antikoerper, IL1H2 antikoerper, Il1f8 antikoerper, interleukin 1 family, member 8 antikoerper, interleukin 36 beta antikoerper, interleukin 36, beta antikoerper, Il1f8 antikoerper, IL36B antikoerper, Il36b antikoerper

Hintergrund: IL-36alpha (IL-1F6), IL-36beta (IL-1F8) and IL-36gamma (IL-1F9) bind to IL-36R (IL-1Rrp2) and IL-1RAcP, activating similar intracellular signals as IL-1. IL-36Ra inhibits the production of proinflammatory cytokines, including IL-12, IL-1beta, IL-6, TNF-alpha and IL-23 induced by IL-36 in BMDC and CD4 T cells. Skin and dendritic cells are targets of the IL-36 interleukins leading to a Th1 response. These cytokines may represent potential targets for immune-mediated inflammatory conditions or, alternatively, could be used as adjuvants in vaccination.